1-13 of 13
Feng Jin, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Nehal Lakhani, MD PhD, Justin Gainor, MD, Manali Kamdar, MD, Philip Fanning, PhD, Pierre Squifflet, MSc, Feng Jin, PhD, Alison J. Forgie, PhD, Hong Wan, PhD, Jaume Pons, PhD, Sophia S Randolph, MDPhD, Won Seog Kim, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
https://doi.org/10.1182/blood-2020-135941
Published: 2020
Journal Articles

A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Nehal Lakhani, MD PhD, Justin Gainor, MD, Manali Kamdar, MD MD, Philip Fanning, PhD, Pierre Squifflet, MSc, Feng Jin, PhD, Hong Wan, PhD, Jaume Pons, PhD, Sophia S Randolph, MD PhD, Won Seog Kim, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1953.
https://doi.org/10.1182/blood-2019-123219
Published: 2019
Journal Articles

Population Pharmacokinetics of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib, in Healthy Volunteers and Patients with B-Cell Malignancies

Helena Edlund, PhD, Marilee Andrew, PhD, Feng Jin, PhD, Priti Patel, MD, Eric Masson, PharmD, J. Greg Slatter, PhD, Sergey Aksenov, PhD, Nidal Al-Huniti, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4997.
https://doi.org/10.1182/blood.V130.Suppl_1.4997.4997
Published: 2017
Journal Articles

Exposure-Response of the Bruton Tyrosine Kinase Inhibitor, Acalabrutinib, in the Treatment of Hematologic Malignancies

Feng Jin, PhD, Ming Yin, PhD, Vinay Mandava, Helena Edlund, PhD, Marilee Andrew, PhD, Priti Patel, MD, Eric Masson, PharmD, Nidal Al-Huniti, PhD, Xiaolin Wang, ScD, J. Greg Slatter, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1268.
https://doi.org/10.1182/blood.V130.Suppl_1.1268.1268
Published: 2017
Journal Articles

Exposure-Response of Idelalisib Administered in Combination with Ofatumumab for the Treatment of Relapsed Chronic Lymphocytic Leukemia

Shringi Sharma, PhD, Ying Guo, PhD, Feng Jin, PhD, Xiaoming Li, PhD, Ronald L. Dubowy, MD, Terry Newcomb, PhD, Srini Ramanathan, PhD
Journal: Blood
Blood (2015) 126 (23): 4172.
https://doi.org/10.1182/blood.V126.23.4172.4172
Published: 2015
Journal Articles

Phase 2 Trial Of GS-9973, a Selective Syk Inhibitor, In Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Jeff P. Sharman, MD, Leonard Klein, MD, Michael Boxer, MD, Kathryn S. Kolibaba, MD, Michael J. Hawkins, MD, Julie A Di Paolo, PhD, Jing Hu, Ph.D, Anita Reddy, PhD, Feng Jin, PhD, Flordeliza Melchor-Khan, BS, Christopher A. Yasenchak, MD
Journal: Blood
Blood (2013) 122 (21): 1634.
https://doi.org/10.1182/blood.V122.21.1634.1634
Published: 2013
Journal Articles

Pharmacokinetics, Metabolism and Excretion Of Idelalisib

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Ellen Kwan, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5570.
https://doi.org/10.1182/blood.V122.21.5570.5570
Published: 2013
Journal Articles

The Pharmacokinetics and Safety Of Idelalisib In Subjects With Moderate Or Severe Hepatic Impairment

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Grace Hisoire, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5571.
https://doi.org/10.1182/blood.V122.21.5571.5571
Published: 2013
Journal Articles

The Pharmacokinetics and Safety Of Idelalisib In Subjects With Severe Renal Impairment

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Grace Hisoire, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5572.
https://doi.org/10.1182/blood.V122.21.5572.5572
Published: 2013
Journal Articles

Evaluation Of The Effect Of Idelalisib On The QT/QTc Interval In Healthy Subjects

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Andie Nichols, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5573.
https://doi.org/10.1182/blood.V122.21.5573.5573
Published: 2013
Journal Articles

Evaluation Of Drug Interaction Profile Of Idelalisib and Its Major Circulating Metabolite, GS-563117, In Healthy Subjects

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Candra Moyer, Sibylle Wilbert, PhD, Bernard Murray, PhD, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5574.
https://doi.org/10.1182/blood.V122.21.5574.5574
Published: 2013
Journal Articles

Pharmacokinetics and Safety Of Idelalisib, a Novel PI3Kδ Inhibitor, In Japanese and Caucasian Subjects

Feng Jin, PhD, Michelle Robeson, ND, Huafeng Zhou, PhD, Candra Moyer, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5575.
https://doi.org/10.1182/blood.V122.21.5575.5575
Published: 2013
Journal Articles

Exposure-Response Of Idelalisib, a Novel PI3Kδ Inhibitor, Administered As Monotherapy In The Treatment Of Hematologic Malignancies

Feng Jin, PhD, Huafeng Zhou, PhD, Lorna Fang, Xiaoming Li, PhD, Terry Newcomb, MD, Roger Dansey, MD, Srini Ramanathan, PhD
Journal: Blood
Blood (2013) 122 (21): 5054.
https://doi.org/10.1182/blood.V122.21.5054.5054
Published: 2013